Moreover, pharmacological blockade of CXCL8 signaling (reparixin) sensitized HNSCC cells to nutrient-starvation therapy (anlotinib) in two xenograft models. The gene discussed is CXCL8; the disease is head and neck squamous cell carcinoma.